Easy MediBot Secured European Patent for U-BOT System
The company cleared a key regulatory hurdle for its uterine suspension robot, with commercialization slated for 2027.
Updated on Sept. 22, 2026 in Robotics
Live Poll
Is now a good time to invest in companies aggressively pursuing international medical patents?
Easy MediBot has officially registered a patent for its U-BOT surgical robot and control system across 19 European countries, including the UK and 18 EU member states. This development follows a patent registration decision received in November 2025.
Why it matters
The registration allows the company to secure intellectual property rights as it prepares for international market entry. This milestone follows domestic product approval and marks a transition toward pursuing broader FDA and CE certifications.
The U-BOT system utilizes voice recognition, remote control, and foot pedal functions to enable precise surgeon control. These 19 newly registered patents follow a total of four previously registered domestic patents.
The players
Easy MediBot
A South Korean robotics firm focused on developing specialized surgical robots for gynecological procedures.
WSI
A publicly traded company on the KOSDAQ market associated with the financial performance of these robotic technologies.
The details
The U-BOT is a surgical robot designed to automate uterine suspension, a procedure where a surgeon reposition the uterus. The system architecture integrates voice recognition, remote control interfaces, and foot pedal actuators to allow the surgeon to maintain control of the uterus during the intervention. Following a registration decision from the European Patent Office in November 2025, the company has now successfully completed national patent procedures in these jurisdictions.
Timeline
November 2025: Received patent registration decision from European Patent Office.
September 22, 2026: WSI stock price rose 29.94 percent to 1,545 Korean won.
Early 2027: Begin preliminary preparations for overseas certifications.
First half of 2027: Targeted commercialization of U-BOT.
The Tech Race
This registration marks a critical expansion for the company, moving from a domestic South Korean footprint toward a broader European presence. The move places the firm in direct competition with established surgical robotics platforms seeking CE certification.
The U-BOT system is currently in the pre-commercial phase and is not yet available for clinical use in European or international hospitals. Surgeons and medical facilities should monitor for pending FDA and CE certification updates throughout 2027.
The takeaway
Securing these patents represents a shift from domestic development to international scaling for the U-BOT platform. Investors and clinical leads should watch for the official filing of FDA and CE certification applications scheduled to begin in early 2027.
What happens next
Easy MediBot plans to begin preliminary preparations for overseas certifications in early 2027, followed by an intended commercial launch of the U-BOT in the first half of 2027.
Further reading
For broader trends in medical automation, explore our Robotics section.
Source note: This article includes information reported by 조선일보.
Live Poll
Is now a good time to invest in companies aggressively pursuing international medical patents?
